Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 23;21(3):201–223. doi: 10.1038/s41573-021-00337-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Springer Nature Limited 2021

This work was supported, in part, by funding from the Alexander von Humboldt Foundation, the European Research Council (ERC) AdG HypoFlam no. 695054 and the German Center for Diabetes Research (DZD e.V.). T.D.M. further received research funding from the German Research Foundation (TRR152 and TRR296). Figures were made using material provided by either Motifolio or Servier Medical Art (Servier), the latter under consideration of a Creative Commons Attribution 3.0 Unported License.

PMC Copyright notice

Fig. 3 — Body weight loss achieved through lifestyle changes, currently approved anti-obesity medications (AOMs) and bariatric surgery (part a) and correlation of drug-induced body weight loss in rodents and humans (part b). Data in panel a refer to liraglutide 3 mg (ref.¹⁷⁶), orlistat²⁸⁹, naltrexone/bupropion²⁹², phentermine/topiramate²⁹¹, semaglutide 1 mg (ref.¹²⁵), semaglutide 2.4 mg (ref.³⁸) and tirzepatide (5 and 15 mg)¹²⁶. Data in panel b refer to naltrexone/bupropion^39,295, orlistat^39,296, lorcaserin^39,297, sibutramine^154,298, liraglutide^39,299, phentermine^121,145, semaglutide^38,123 and tirzepatide^122,127.